clarithromycin

10 January, 2025

Clarithromycin for improved clinical outcomes in community-acquired pneumonia: A subgroup analysis of the ACCESS trial

2025-01-10T13:53:31+03:00By hiss|Categories: Publications, Therapeutics|Tags: clarithromycin, pneumonia|

Karolina Akinosoglou, Konstantinos Leventogiannis, Elisavet Tasouli, Nikolaos Kakavoulis, Georgios Niotis, Sarantia Doulou, Lamprini Skorda, Konstantina Iliopoulou, Anna Papailiou, Paraskevi Katsaounou, Vassiliki Rapti, George Chrysos, Theodoros Seferlis, Styliani Gerakari, Konstantina Dakou, Ilias C. Papanikolaou, Haralampos Milionis, Samantha Kewitz, Sara Georgiadou, Theano Kontopoulou, Vasiliki Tzavara, Antonio Torres, Michael S. Niederman, Evangelos J. Giamarellos-Bourboulis Int

13 February, 2024

REACT

2025-03-13T15:59:08+03:00By hiss|Categories: Ongoing, Sepsis and severe infections, Studies|Tags: CAP, clarithromycin, pneumonia, Sepsis, suPAR|

Ongoing study Official Study Title BiomarkeR-guided EArly Clarithromycin Treatment to prevent sepsis progression in community-acquired pneumonia: The REACT Randomized clinical trial Brief Description The primary objective of the REACT RCT is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of

4 January, 2024

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial

2024-04-01T11:51:43+03:00By hiss|Categories: Multicenter studies in Greece, Publications, Therapeutics|Tags: clarithromycin, clinical trial, pneumonia|

Evangelos J. Giamarellos-Bourboulis, Athanasios Siampanos, Amalia Bolanou, Sarantia Doulou, Nikolaos Kakavoulis, Konstantinos Tsiakos, Sokratis Katopodis, Georgios Schinas, Lamprini Skorda, Zoi Alexiou, Konstantinos Armenis, Paraskevi Katsaounou, George Chrysos, Aikaterini Masgala, Garyphalia Poulakou, Nikolaos Antonakos, Asimina Safarika, Miltiades Kyprianou, Konstantina Dakou, Styliani Gerakari, Ilias C Papanikolaou, Prof Haralampos Milionis, Prof Markos Marangos, Prof George N Dalekos,

18 June, 2022

Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial

2023-02-16T12:38:06+03:00By hiss|Categories: Publications|Tags: clarithromycin, clinical trial, Sepsis|

Eleni Karakike, Brendon P Scicluna, Maria Roumpoutsou, Ioannis Mitrou, Niki Karampela, Athanasios Karageorgos, Konstantinos Psaroulis, Eleni Massa, Achillefs Pitsoulis, Panagiotis Chaloulis, Evanthia Pappa, Irene T Schrijver, Frantzeska Frantzeskaki, Malvina Lada, Nicolas Dauby, David De Bels, Ioannis Floros, Souzana Anisoglou, Eleni Antoniadou, Maria Patrani, Glykeria Vlachogianni, Eleni Mouloudi, Anastasia Antoniadou, David Grimaldi, Thierry Roger, W

1 December, 2021

Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial

2023-02-16T13:22:30+03:00By hiss|Categories: Publications|Tags: clarithromycin, clinical trial, COVID-19|

Konstantinos Tsiakos, Antonios Tsakiris, Georgios Tsibris, Pantazis-Michael Voutsinas, Periklis Panagopoulos, Maria Kosmidou, Vasileios Petrakis, Areti Gravvani, Theologia Gkavogianni, Eleftherios Klouras, Konstantina Katrini, Panagiotis Koufargyris, Iro Rapti, Athanassios Karageorgos, Emmanouil Vrentzos, Christina Damoulari, Vagia Zarkada, Chrysanthi Sidiropoulou, Sofia Artemi, Anastasios Ioannidis, Androniki Papapostolou, Evangelos Michelakis, Maria Georgiopoulou, Dimitra-Melia Myrodia, Panteleimon Tsiamalos, Konstantinos Syrigos, George Chrysos,

1 September, 2021

The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece

2024-04-02T18:01:32+03:00By hiss|Categories: Publications, Therapeutics|Tags: clarithromycin, COVID-19, pneumonia|

Evangelos J. Giamarellos-Bourboulis, George L Daikos, Panagiotis Gargalianos, Charalambos Gogos, Marios Lazanas, Periklis Panagopoulos, Garyphallia Poulakou, Helen Sambatakou, Michael Samarkos Infectious Diseases and Therapy 2021 Sep;10(3):1081-1095 DOI: 10.1007/s40121-021-00471-1Download pdf 🡇 Funding The study was funded by the Hellenic Institute for the Study of Sepsis. No Rapid Service Fee was received by the

1 January, 2021

ACCESS

2024-02-07T15:52:51+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: clarithromycin, pneumonia|

Completed study Official Study Title A randomized clinical trial of oral Clarithromycin in Community-acquired pneumonia to attenuatE inflammatory responseS and improve outcomeS Brief Description Based on evidence coming from observational studies that addition of macrolides in the treatment regimen of community-acquired pneumonia (CAP) exhibits some anti-inflammatory mode of action, this RCT is aiming to

1 May, 2020

ACHIEVE

2023-01-09T12:17:31+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: clarithromycin, COVID-19|

Completed study Official Study Title Anti-inflammatory ClaritHromycin to ImprovE SARS-CoV-2 (COVID-19) infection Early: The ACHIEVE open-label non-randomized clinical trial Brief Description ACHIEVE is an open non-randomized clinical trial aiming to prove that the addition of oral clarithromycin to treatment regimen of COVID-19 is associated with early clinical improvement and attenuation of the high inflammatory

1 January, 2020

Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study

2023-02-16T14:31:00+03:00By hiss|Categories: Publications, Therapeutics|Tags: azithromycin, clarithromycin, pneumonia|

Evdoxia Kyriazopoulou, Dimitrios Sinapidis, Stamatios Halvatzis, Dimitrios Velissaris, Nikolaos Alexiou, Vasilios Kosmas, Maria-Evangelia Adami, Miltiades Kyprianou, Aikaterini Kyprianou, Aggelos Stefos, Malvina Lada, Pantelis Koutoukas, Maria Pavlaki, Anna Kyriakoudi, Anna Makina, Charalambos Gogos, Michael S Niederman, Evangelos J. Giamarellos-Bourboulis International Journal of Antimicrobial Agents 2020 Jan;55(1):105836 DOI: 10.1016/j.ijantimicag.2019.10.017View article 🡇 Funding The works were

1 December, 2017

INCLASS

2023-01-09T12:15:00+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: clarithromycin, Sepsis|

Completed study Official Study Title A double-blind, randomized, placebo-controlled clinical study of the efficacy of INtravenous CLArithromycin as adjunctive treatment in patients with Sepsis and respiratory and multiple organ dysfunction Syndrome Brief Description INCLASS is a randomized clinical trial aiming to compare the efficacy of intravenous clarithromycin over placebo in patients with sepsis and